CP
VCYT icon

Castleview Partners’s Veracyte VCYT Stock Holding History

Castleview Partners’s Portfolio VCYT Stock Details VCYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,268
Closed -$91.7K – 552
2024
Q4 		$91.7K Sell
2,268
-282
-11% -$10.7K 0.05% 265
2024
Q3 		$86.8K Buy
+2,550
New +$71.7K 0.05% 247

Other funds holding VCYT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Castleview Partners's VCYT Position: Q1 2025 in Review

Castleview Partners sold out of Veracyte (VCYT) in Q1 2025, closing a stake of 2,268 shares — an estimated $91.7K sold.

Castleview Partners first reported a position in VCYT in Q3 2024 and held it in 2 quarters. The position peaked at $91.7K in Q4 2024. 287 funds tracked by Wall St. Rank hold VCYT as of Q1 2025.

  • Castleview Partners reported no remaining Veracyte position as of Q1 2025 after selling out during the quarter.
  • Castleview Partners sold 2,268 Veracyte shares in Q1 2025, an estimated $91.7K.
  • Castleview Partners first reported a position in Veracyte in Q3 2024 and held it in 2 quarters.
  • Castleview Partners's Veracyte position peaked at $91.7K in Q4 2024.
  • 287 funds tracked by Wall St. Rank held Veracyte as of Q1 2025.

Based on Castleview Partners's 13F filing for Q1 2025, filed 22 Apr 2025.